Press Room
  Date Title View
Apr 27, 2000
San Mateo, CA, April 27, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that first quarter 2000 sales of ZADAXIN, the Company's lead immunotherapy, were $3,499,000, an increase of 122% over first quarter 1999 ZADAXIN sales of $1,577,000. For the first quarter of 2000, the net loss of $875,000 decreased 67% when compare...
PDF
Apr 13, 2000
San Mateo, CA, April 13, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the approval of ZADAXIN, its lead immunotherapy, in South Korea, one of the world's largest pharmaceutical markets. The South Korean approval is for use of ZADAXIN as an influenza vaccine adjuvant by individuals wit...
PDF
Apr 6, 2000
San Mateo, CA, April 6, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that a study published in the peer-reviewed journal Melanoma Research (Volume 10, Issue 2, April 2000) suggests that ZADAXINÃ’, SciClone's lead immunotherapy, increases the effectiveness of chemotherapy for metastatic...
PDF
Mar 22, 2000
San Mateo, CA, March 22, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status to ZADAXIN®, SciClone's lead immunotherapy, for the treatment of hepatocellular carcinoma,...
PDF
Mar 17, 2000
San Mateo, CA, March 17, 2000 - SciClone Pharmaceuticals (Nasdaq: SCLN) today announced that ZADAXIN, the Company's lead immunotherapy, has been approved for marketing in Thailand, Laos and Malta. ZADAXIN now is approved for marketing in 19 countries, principally for treatment of hepatitis B and hepatit...
PDF
Mar 13, 2000
Rome, Italy and San Mateo, CA, March 13, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) and Sigma-Tau S.p.A., the leading research-based Italian pharmaceutical company, announced today they have signed an expanded development and marketing partnership for ZADAXINÃ’, SciClone's host immune system enhance...
PDF
Mar 1, 2000
San Mateo, CA, March 1, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today that a study published in the peer-reviewed European Journal of Immunology (March 2000, Volume 30, Issue 3) shows that ZADAXIN® (thymosin alpha 1) directly increases the immune sys...
PDF
Feb 23, 2000
San Mateo, CA, February 23, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) announced today at the 12th Annual Cruttenden Roth Growth Stock Conference that it has been awarded a $300,000 grant to study SCV-07, the Company's new immunomodulator, as a potential treatment for tuberculosis (TB), the most co...
PDF
Feb 15, 2000
San Mateo, CA, February 15, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced plans to move forward with the next stage of its phase 2 development program for CPX, a novel PRT (protein repair therapy) for cystic fibrosis (CF). SciClone, working closely with scientists and clinical investig...
PDF
Feb 3, 2000
San Mateo, CA, February 3, 2000 -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced results for the fourth quarter and year ended December 31, 1999.For the year, the Company reported total revenue of $9,397,000, a 152% increase over the $3,725,000 reported for 1998. Sales of ZADAXINÃ’, the Company's host immune system enhancer (...
PDF
FirstPrevious
...
40
NextLast